These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 9088592)
21. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Parker JO Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014 [TBL] [Abstract][Full Text] [Related]
22. [Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)]. Jansen W; Prenzel R; Kümper H; Weidmann B; Tauchert M Z Kardiol; 1989; 78 Suppl 2():72-8; discussion 115-7. PubMed ID: 2511697 [TBL] [Abstract][Full Text] [Related]
23. [Intraindividual dose-response relationship of sustained-release Elantan]. Kenedi P Z Kardiol; 1986; 75 Suppl 3():77-9. PubMed ID: 3541420 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers. Niopas I; Daftsios AC; Nikolaidis N Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645 [TBL] [Abstract][Full Text] [Related]
26. [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate]. Martsevich SIu; Semenova IuE; Alimova EV; Dmitrieva nA; Kozyreva MP; Koniakhina IP; Lukina IuV; Egorov VA Kardiologiia; 2005; 45(11):42-5. PubMed ID: 16353064 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680 [TBL] [Abstract][Full Text] [Related]
28. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects. Niopas I; Daftsios AC; Nikolaidis N Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069 [TBL] [Abstract][Full Text] [Related]
29. Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group. Zwinderman AH; Cleophas TJ; van der Sluijs H; Niemeyer MG; Buunk BP; van der Wall EE Angiology; 1999 Dec; 50(12):963-9. PubMed ID: 10609762 [TBL] [Abstract][Full Text] [Related]
30. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation. Olsson G; Allgén J; Amtorp O; Nyberg G; Parker JO Eur Heart J; 1992 Jun; 13(6):814-7. PubMed ID: 1623873 [TBL] [Abstract][Full Text] [Related]
31. Recent developments in the use of nitrates for treatment of angina pectoris. Ankier SI; Warrington SJ; Sneddon JM J Int Med Res; 1988; 16(4):249-56. PubMed ID: 3139481 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of isosorbide mononitrate. Abshagen UW Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102 [TBL] [Abstract][Full Text] [Related]
33. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil. Stauch M; Grossmann G; Wanjura D; Adam WE Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712 [TBL] [Abstract][Full Text] [Related]
34. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. Thomson AH; Miller SH; Green ST; Whiting B Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048 [TBL] [Abstract][Full Text] [Related]
35. [The efficacy of 2 new drug forms of isosorbide-5-mononitrate in patients with stable stenocardia of effort]. Metelitsa VI; Martsevich SIu; Kutishenko NP; Kozyreva MP; Blagodatskikh SV; Simkhaev LS; Slastnikova ID; Vakulovskaia MK Ter Arkh; 1994; 66(8):22-5. PubMed ID: 7985147 [No Abstract] [Full Text] [Related]
36. Association of GSTM1 null polymorphism with isosorbide-5-mononitrate cardiovascular response and involvement of CGRP in healthy Chinese male volunteers. Guo R; Chen L; Li L; Guo X; Sun J; Xiong XM; Cheng ZN; Li YJ; Chen XP Pharmacogenet Genomics; 2011 Mar; 21(3):142-51. PubMed ID: 21278620 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects. Jin C; Jeon JY; Im YJ; Jeong JA; Kim Y; Chae SW; Bentz J; Kumke T; Kim MG Int J Clin Pharmacol Ther; 2015 Jan; 53(1):97-106. PubMed ID: 25492848 [TBL] [Abstract][Full Text] [Related]
38. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. Muck B; Bonn R; Rietbrock N Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720 [TBL] [Abstract][Full Text] [Related]
39. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Wagner F; Siefert F; Trenk D; Jähnchen E Eur J Clin Pharmacol; 1990; 38 Suppl 1():S53-9. PubMed ID: 2354713 [TBL] [Abstract][Full Text] [Related]
40. [The relationship between the isosorbide-5-mononitrate concentration and its antianginal effect following the administration of regular and prolonged-action drug forms in patients with stenocardia of effort]. Blagodatskikh SV; Martsevich SIu; Metelitsa VI; Kutishenko NP; Kozyreva MP; Simkhaev LS; Slastinkova ID; Vakulovskaia MK Eksp Klin Farmakol; 1995; 58(3):25-7. PubMed ID: 7663289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]